.
.
.
.

Coronavirus: Argentina joins Chinese COVID-19 vaccine trial

Published: Updated:

Argentina joined Peru, Morocco and the United Arab Emirates in approving Phase 3 clinical trials for a coronavirus vaccine developed by China National Biotec Group (CNBG), the company said late Friday.

As China forges ahead in the global race to develop a vaccine to curb the COVID-19 pandemic and as cases within China dwindle, CNBG needs research participants from other countries for testing.

Read the latest updates in our dedicated coronavirus section.

Phase 3 trials, which usually involve several thousand participants, allow researchers to gather data on the efficacy of potential vaccines for final regulatory approvals.

Read more:

Coronavirus: WHO begins talks with Russia about COVID-19 vaccine

UAE’s G42 to work with Israeli NanoScent to develop COVID-19 detector from scent

CNBG will partner with Argentina’s ELEA in the vaccine trial, the Chinese company said in a statement late Friday.

For all the latest headlines, follow our Google News channel online or via the app.

The experimental vaccine by CNBG, a unit of state-owned pharmaceutical giant China National Pharmaceutical Group (Sinopharm), received approval from the UAE in June for a Phase 3 trial and has since recruited 15,000 volunteers.

The company said on Thursday that Peru and Morocco also approved the trials.

CNBG has also obtained approval from Bahrain for a Phase 3 study designed to involve around 6,000 participants.